Craft
  • Home
  •  / Dare Bioscience
Dare Bioscience

Dare Bioscience

Revenue

$766 K

FY, 2016

Market Capitalization

$79.7 M

2022-09-23

Dare Bioscience Summary

Company summary

Overview
Dare Bioscience (formerly Cerulean Pharma) is a clinical-stage oncology-focused company developing nanoparticle-drug conjugates, is committed to improving treatment for people living with cancer. The Company applies Dynamic Tumor Targeting Platform to create a growing portfolio of nanoparticle-drug conjugate designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations.
Type
Public
Founded
2006
HQ
San Diego, CA, US | view all locations
Website
https://www.darebioscience.com
Cybersecurity rating
Sectors

Key people

  • Susan L. Kelley

    Susan L. Kelley, Director

    • Jessica Grossman

      Jessica Grossman, Director

      • Scott Eliasof, Vice President, Research

        • William H. Rastetter

          William H. Rastetter, Lead Independent Director, Chairman of the Board

          LocationsView all

          1 location detected

          • San Diego, CA HQ

            United States

            3655 Nobel Dr #260

          Dare Bioscience Financials

          Summary financials

          Revenue (Q2, 2022)
          $10.0M
          Net income (Q2, 2022)
          $414.0K
          Cash (Q2, 2022)
          $32.1M
          EBIT (Q2, 2022)
          $384.3K
          Enterprise value
          $48.7M

          Footer menu